Key Highlights

  • Q1 2026 HIFU Revenue grew 78% year-over-year to $11.6 million, a company record.
  • S. Focal One procedures grew 53% and system shipments rose 83%, indicating strong institutional Demand.
  • Positive HIFI-2 study data support Focal One as a non-invasive treatment for recurrent prostate cancer post-radiation.
  • The combination of Volume growth and clinical validation reinforces the company's competitive moat.
  • Shares rose 16% to $4.16, reflecting growing investor conviction in the HIFU platform's commercial trajectory.

 

EDAP TMS delivered a first-quarter performance that demonstrated the commercial momentum of its Focal One robotic high-intensity focused ultrasound platform in convincing terms, reporting record HIFU revenues of $11.6 million — a 78% year-over-year increase — alongside compelling clinical data from the HIFI-2 study. Shares closed up 16% at $4.16.

The operational metrics were uniformly strong. U.S. Focal One procedure volumes grew 53% year-over-year, reflecting expanding clinical adoption among urologists and radiation oncologists managing localised and recurrent prostate cancer. More striking still was the 83% growth in system shipments — a leading indicator that institutional customers are committing Capital to build or expand HIFU programmes, a decision that generates durable, recurring procedure revenue once the installed base is established.

HIFU's clinical appeal in prostate cancer management lies in its ability to ablate targeted tissue with millimetre precision using ultrasound energy delivered transcutaneously, avoiding the ionising radiation of external beam radiotherapy and the surgical morbidity of radical prostatectomy. In the specific context of locally recurrent prostate cancer following prior radiation — a situation where retreatment Options are severely constrained by accumulated tissue damage — Focal One's non-invasive profile is particularly compelling.

The HIFI-2 study data, presented alongside the commercial results, provide the clinical evidence base that underpins this positioning. Positive outcomes in a formally conducted study of Focal One for post-radiation recurrence address one of the most challenging unmet needs in urological oncology and offer EDAP a differentiated narrative for hospital capital equipment committees and payors evaluating reimbursement policies.

EDAP's commercial model benefits from a high-value installed base dynamic: Focal One systems require ongoing consumables and service contracts, and growing procedure volumes generate revenue that is relatively predictable once the Investment/">Capital Investment has been made. The 83% system shipment growth suggests the installed base is expanding rapidly, which should translate into structurally higher procedure revenue in subsequent quarters.

For investors tracking the MedTech space, EDAP's results offer a case study in how clinical validation and commercial execution can compound together. The HIFI-2 data remove a layer of clinical risk; the record revenues demonstrate the market is already responding. The trajectory, on Friday's evidence, is firmly upward.

EDAP (Nasdaq) closed at $4.16, +16% on May 8, 2026. This article is for informational purposes only and does not constitute investment advice.